Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2637468 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CNR1CNR2TRPV1 | |
| SCHEMBL2637391 | 0.93 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL22403747 | 0.93 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL2637867 | 0.93 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL2637389 | 0.93 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL23017054 | 0.93 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL1892418 | 0.93 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL21235330 | 0.92 | ALDH1A1 (0.49) | ALDH1A1CNR1CNR2 | |
| SCHEMBL1934038 | 0.92 | ALDH1A1 (0.58) | ALDH1A1CNR1CNR2 | |
| SCHEMBL1934041 | 0.92 | ALDH1A1 (0.58) | ALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569276-B1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2021-02-24 | — | — | EP | disclosed |
| US-20200282060-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-09-10 | — | — | US | disclosed |
| US-20170151333-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-06-01 | — | — | US | disclosed |
| US-8865675-B2 | Compositions and methods for silencing apolipoprotein B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2014-10-21 | — | — | US | disclosed |
| US-20130123338-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130123339-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS INC (CA) | 2013-05-16 | — | — | US | disclosed |
| EP-2569276-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | Protiva Biotherapeutics Inc. (CA) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011141705-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123338-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PLIN3, CETP, LDLR | ALDH1A1 4646/4885CNR1 4067/4885CNR2 4151/4885 |
| US-20200282060-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PLIN3, CETP, LDLR | ALDH1A1 4646/4885CNR1 4067/4885CNR2 4151/4885 |
| US-20130123339-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | APOB, LDLR, APOL1 | ALDH1A1 3439/4885CNR1 3280/4885CNR2 3790/4885 |
| US-20170151333-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PLIN3, CETP, LDLR | ALDH1A1 4646/4885CNR1 4067/4885CNR2 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.